DRUGS

Scale from 0 to 100

Revised Cardiac Risk Index for Pre‑Operative Risk: Estimates risk of major cardiac complications after noncardiac surgery.

DRUGS: Insulin lowers blood glucose by increasing peripheral glucose uptake.

Number of drugs
One+1Two+2Three+3Four+4
Identific drug 1
Not able0Able+1
Access drug 1
Not able0Able+1
Dosage drug 1
Not able0Able+1
Timing drug 1
Not able0Able+1
Identific drug 2
Not able0Able+1
Access drug 2
Not able0Able+1
Dosage drug 2
Not able0Able+1
Timing drug 2
Not able0Able+1
Identific drug 3
Not able0Not applicable0Able+1
Access drug 3
Not able0Not applicable0Able+1
Dosage drug 3
Not able0Not applicable0Able+1
Timing drug 3
Not able0Not applicable0Able+1
Identific drug 4
Not able0Not applicable0Able+1
Access drug 4
Not able0Not applicable0Able+1
Dosage drug 4
Not able0Not applicable0Able+1
Timing drug 4
Not able0Not applicable0Able+1

Indications for Use

Used to stratify perioperative MACE risk in adults undergoing non‑cardiac surgery, especially elective or time‑sensitive procedures. Helps identify patients with elevated cardiac risk (RCRI >1 ≈ ≥1% MACE) to guide decisions on need for further testing, optimization of medical therapy, and perioperative planning (2024 AHA/ACC guideline 1). Not reliable for vascular or emergent surgery.

Insights & Cautions

Continue chronic beta‑blockers and avoid new initiation within 7 days; never start on day of surgery due to harm 1 [Level I evidence]. Hold SGLT2 inhibitors 3–4 days pre‑op to prevent ketoacidosis 2 [Level I evidence]. Withhold ACEi/ARB 24 hours pre‑op in hypertension to reduce intraoperative hypotension 3 [Level I evidence]. Avoid initiating clonidine; continuation only. Manage antiplatelets/anticoagulants per procedural bleeding/thrombotic risk.